Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.
Aim(s): To investigate the role of CA 19-9 in prognostication for PNETs
Materials and methods: 103 PNET patients with serum CA 19-9 measured at diagnosis were studied. Histology was reviewed to confirm diagnosis and 3 cases of tumours with adenocarcinomatous features were excluded. Clinical notes were studied to identify jaundice, pancreatitis, cirrhosis and other parameters.
Conference: 12th Annual ENETS Conference 2015 (2015)
Presenting Author: Logan Mills
To read results and conclusion, please login ...
Further abstracts you may be interested in